Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2.
about
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsTau clearance mechanisms and their possible role in the pathogenesis of Alzheimer diseaseThe modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration.Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's diseaseSpecific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L miceImplicating calpain in tau-mediated toxicity in vivo.The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration.NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation.Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's diseaseCalpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathiesExposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing.Calpain dysregulation in Alzheimer's diseaseCalpain-mediated cleavage of DARPP-32 in Alzheimer's disease.Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease.SNPs in CAST are associated with Parkinson disease: a confirmation study.Accumulation of human full-length tau induces degradation of nicotinic acetylcholine receptor α4 via activating calpain-2.Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.Attenuation of low dose methylmercury and glutamate induced-cytotoxicity and tau phosphorylation by an N-methyl-D-aspartate antagonist in human neuroblastoma (SHSY5Y) cells.Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells.Identification and characterization of PEBP as a calpain substrate.Proteasome inhibition and Tau proteolysis: an unexpected regulation.A functional genomic study on NCI's anticancer drug screen.The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.Axonal Degeneration in Tauopathies: Disease Relevance and Underlying Mechanisms.Calpain-2 as a therapeutic target for acute neuronal injury.Dysregulation of TrkB Receptors and BDNF Function by Amyloid-β Peptide is Mediated by Calpain.
P2860
Q26771736-B743476A-195C-4B35-AFDA-D1E1DD8A100DQ26995276-EE6CAA01-D1AE-4406-9D5A-BCEFBBF06F96Q33264215-8797B70B-C1C2-4CBF-8892-F5A6EF2445A8Q33640651-8075299A-FC0C-4EA9-87AE-87CA1B2F3184Q33855897-1629C60D-1F9A-4954-8ED6-CC9A5967E08DQ33865294-E2FEFECD-DAA4-44E1-A4D1-B025C74E0971Q34000095-F3A35F95-16F4-43B4-877E-6F873F7030BEQ34316318-C669C44E-347F-475B-B9E8-7ACF1DD0A661Q34479707-82EAC531-748E-4BC8-929D-D0EC42C23569Q35063341-EA4A83D1-6B6A-4702-8681-9AB68F773BC0Q35103074-05C9F7A7-4559-4ED6-AE61-23DA2603A7AAQ35136746-8D62CA1D-DCD6-41D8-B198-0090141ACBB9Q35147567-43AA1CDA-1572-4D07-9A00-3DCF0443396CQ35361462-C6AFDD51-CAFB-4EE4-8CDB-334D7E1AECE4Q36057664-A3453513-D6DB-483C-B62D-E57E37C1CE14Q36266206-E47A38CC-203F-4C4A-A3CE-F43BEC4DDABBQ36554860-4DED9D7D-E266-46FE-89E9-9629711E3AA6Q36936945-8AC4E31B-254B-4C47-A865-2B62FF2A4410Q36985823-93E4C86D-8451-4282-A49D-D75F9BC2F76DQ38319146-8362D0A6-5076-424E-823B-75EDD0B34260Q39462697-F51ED170-587C-4878-80F3-DDA032248BD5Q39604775-8200358C-87CE-4846-9D47-12F3E41573CDQ40224274-9A0D9F84-4C3F-489D-842B-1B670AFEAF16Q40476899-5AC0D876-665C-4425-905A-D5B85D866376Q44782550-7E21DF25-965E-4851-BA25-B58D7868363EQ46669000-63F471B3-C7D4-42CD-A4C1-CE41D9CB894EQ46985283-E0D7AEA2-6FC6-478F-8452-E40ED0F9F4F9Q47370941-00966C89-071C-49BA-AF9E-AE458B07B910Q48769291-E964BF1D-893D-4693-9F5F-76976A448900
P2860
Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Calpain activation in neurodeg ...... the active form of calpain 2.
@en
Calpain activation in neurodeg ...... the active form of calpain 2.
@nl
type
label
Calpain activation in neurodeg ...... the active form of calpain 2.
@en
Calpain activation in neurodeg ...... the active form of calpain 2.
@nl
prefLabel
Calpain activation in neurodeg ...... the active form of calpain 2.
@en
Calpain activation in neurodeg ...... the active form of calpain 2.
@nl
P2093
P921
P1476
Calpain activation in neurodeg ...... the active form of calpain 2.
@en
P2093
Emil Adamec
Jean P Vonsattel
Panaiyur Mohan
Ralph A Nixon
P2888
P304
P356
10.1007/S00401-002-0528-6
P577
2002-03-23T00:00:00Z
P6179
1024660031